Associations of physiologic myocardial 18F-FDG uptake with fasting duration, HbA1c, and regular exercise

Can FDG PET Serve as a Clinically Relevant Tool for Detecting Active Non-sarcoidotic Myocarditis?

The diagnostic work-up for myocarditis largely depends on non-invasive imaging because of the low yield of endomyocardial biopsy. In addition, differentiation among possible impressions is essential because of its non-specific clinical presentations. This ambiguity has led to the predominant use of cardiac magnetic resonance imaging techniques in the management of myocarditis, particularly during the global pandemic. Despite the unique ability of F-18 fluorodeoxyglucose positron emission tomography to visualize and quantify active myocardial inflammation, which has been well established in cardiac sarcoidosis, its diagnostic contribution in non-sarcoidotic myocarditis remains uncertain. This article reviews the current evidence on the non-invasive imaging diagnosis of non-sarcoidotic myocarditis and discusses the potential role of F-18 fluorodeoxyglucose positron emission tomography as a clinically relevant imaging tool.

Various Aspects of Fasting on the Biodistribution of Radiopharmaceuticals

It is demonstrated that fasting can alter the biodistribution of radiopharmaceuticals in nuclear medicine. Various studies have highlighted that fasting is interpreted to be easy for physicians during PET study, fasting is one of the most important factors determining the usefulness of this protocol. It is well documented that fasting can suppress normal ¹⁸F-FDG PET uptake during nuclear cardiology. However, there is no consensus about the usefulness of fasting on radiopharmaceuticals, especially on ¹⁸F-FDG in PET imaging, but special attention should be paid to the setting of the fasting duration. Nevertheless, it does seem we still need extensive clinical studies in the future. The present study aims to review the various aspects of fasting, especially metabolic alteration on radiopharmaceutical biodistribution. In this study, we focused more on the effect of fasting on ¹⁸F-FDG biodistribution, which alters its imaging contrast in cardiology and cancer imaging. Therefore, shifting substrate metabolism from glucose to free fatty acids during fasting can be an alternative approach to suppress physiological myocardial uptake.

Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients

BACKGROUND

Dynamic whole-body (D-WB) FDG PET/CT is a recently developed technique that allows direct reconstruction of multiparametric images of metabolic rate of FDG uptake (MR_FDG) and "free" FDG (DV_FDG). Multiparametric images have a markedly different appearance than the conventional SUV images obtained by static PET imaging, and normal values of MR_FDG and DV_FDG in frequently used reference tissues and organs are lacking. The aim of this study was therefore to: (1) provide an overview of normal MR_FDG and DV_FDG values and range of variation in organs and tissues; (2) analyse organ time-activity curves (TACs); (3) validate the accuracy of directly reconstructed MR_FDG tissue values versus manually calculated K_i (and MR_FDG) values; and (4) explore correlations between demographics, blood glucose levels and MR_FDG values. D-WB data from 126 prospectively recruited patients (100 without diabetes and 26 with diabetes) were retrospectively analysed. Participants were scanned using a 70-min multiparametric PET acquisition protocol on a Siemens Biograph Vision 600 PET/CT scanner. 13 regions (bone, brain grey and white matter, colon, heart, kidney, liver, lung, skeletal muscle of the back and thigh, pancreas, spleen, and stomach) as well as representative pathological findings were manually delineated, and values of static PET (SUV), D-WB PET (K_i, MR_FDG and DV_FDG) and individual TACs were extracted. Multiparametric values were compared with manual TAC-based calculations of K_i and MR_FDG, and correlations with blood glucose, age, weight, BMI, and injected tracer dose were explored.

RESULTS

Tissue and organ MR_FDG values showed little variation, comparable to corresponding SUV variation. All regional TACs were in line with previously published FDG kinetics, and the multiparametric metrics correlated well with manual TAC-based calculations (r² = 0.97, p < 0.0001). No correlations were observed between glucose levels and MR_FDG in tissues known not to be substrate driven, while tissues with substrate driven glucose uptake had significantly correlated glucose levels and MR_FDG values.

CONCLUSION

The multiparametric D-WB PET scan protocol provides normal MR_FDG values with little inter-subject variation and in agreement with manual TAC-based calculations and literature values. The technique therefore facilitates both accurate clinical reports and simpler acquisition of quantitative estimates of whole-body tissue glucose metabolism.

Prediction of cardiac events following concurrent chemoradiation therapy for non-small-cell lung cancer using FDG PET

OBJECTIVE

No imaging biomarkers are available for the prediction of cardiac events following concurrent chemoradiation therapy (CCRT) for non-small-cell lung cancer (NSCLC). We evaluated whether F-18 fluorodeoxyglucose positron emission tomography (FDG PET) early after CCRT, in addition to cardiac dosimetry, could predict late cardiac events in NSCLC.

METHODS

We retrospectively enrolled 133 consecutive patients with locally advanced, unresectable stage III NSCLC, who underwent FDG PET early after CCRT and survived at least 6 months. The primary endpoint was cardiac event ≥ grade 2 according to the Common Terminology Criteria for Adverse Events (version 5.0). Myocardial FDG uptake was measured and its association with the risk of cardiac events was evaluated.

RESULTS

FDG PET was performed after a median interval of 11 days of completing CCRT. Overall, 42 (32%) patients experienced cardiac events during a median follow-up of 45 months. The mean heart dose, maximum left ventricular (LV) standardized uptake value (SUV), changes in maximum and mean LV SUV, right ventricular uptake, tumor stage, white blood cell count, and diabetes were associated with cardiac events in univariable analysis. In multivariable analysis, maximum LV SUV (cutoff > 12.84; hazard ratio [95% confidence interval] = 2.140 [1.140-4.016]; p = 0.018) was an independent predictor of cardiac events along with the mean heart dose (> 11.1 Gy; 3.646 [1.792-7.417]; p < 0.001) and tumor stage (IIIB; 1.986 [1.056-3.734]; p = 0.033). It remained predictive of cardiac events in those with higher mean heart dose but not in those with lower mean heart dose.

CONCLUSIONS

Early FDG PET after CCRT for NSCLC could aid in predicting late cardiac events, especially in patients with higher mean heart dose.